Carter, S. M., Degeling, C., Doust, J., & Barratt, A. (2016). A definition and ethical evaluation of overdiagnosis. Journal of Medical Ethics. doi:10.1136/medethics-2015-102928

(see also commentaries and our response under Related Articles at the bottom of the page)

Degeling, C., Carter, S. M., & Rychetnik, L. (2016). All care, but whose responsibility? Community juries reason about expert and patient responsibilities in prostate-specific antigen screening for prostate cancer. Health:published August 3, 2016 doi:10.1177/1363459316660862.

Carter, S. M. (2016). Ethical aspects of cancer screening. Cancer Forum, 40(2), 105-109.

Jacklyn G, Glasziou P, Macaskill P, Barratt A.  Meta-analysis of breast cancer mortality benefit and over diagnosis adjusted for adherence: improving information on the effects of attending screening mammography.  British Journal of Cancer. 2016; Apr 28. doi: 10.1038/bjc.2016.90. [Epub ahead of print]

Pickles K, Carter SM, Rychetnik L, McCaffery K, Entwhistle VA. General practitioners’ experiences of, and responses to, uncertainty in prostate cancer screening: insights from a qualitative study.  PLoS ONE. 2016;11(4):e0153299.

Parker LM, Carter SM. The role of socially embedded concepts in breast cancer screening: an empirical study with experts. Public Health Ethics. 2016; Apr 19:phw012.

Barratt A, Jacklyn GL. Challenges in Understanding and Quantifying Overdiagnosis and Overtreatment. In: Houssami N, Miglioretti D, editors. Breast Cancer Screening: An Examination of Scientific Evidence. London, UK: Elsevier; 2016.

Parker LM, Carter SM. Social and ethical considerations in breast cancer screening.  In: Houssami N, Miglioretti D, editors. Breast cancer screening: the scientific evidence. London, UK:Elsevier; 2016.

Carter SM, Rogers W, Heath I, Degeling C, Doust J, Barratt A. The challenge of overdiagnosis begins with its definition. BMJ. 2015;350:h869.

Degeling C, Rychetnik L, Pickles K, Doust J, Gardiner R, Glasziou P, Newson A, Thomas R, Carter S. “What should happen before asymptomatic men decide whether or not to have a PSA test?” A report on three community juries. Medical Journal of Australia, 2015, 203(8), 335

Parker LM, Rychetnik L, Carter SM. The role of communication in breast cancer screening: a qualitative study with Australian experts. BMC Cancer. 2015;15(1):741

Pickles K, Carter SM, Rychetnik L. Doctors’ approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. BMJ Open. 2015;5:e006367.

Degeling C, Carter SM, and Rychetnik L. Which public and why deliberate? – A scoping review of public deliberation in public health and health policy research.  Social Science & Medicine 2015;131:114-21.

Parker LM, Rychetnik L, Carter S.  Framing overdiagnosis in breast screening: a qualitative study with Australian experts.  BMC Cancer. 2015;15(1):606.

Williams JH, Carter SM, Rychetnik L. ‘Organised’ cervical screening 45 years on: How consistent are organised screening practices? European Journal of Cancer. 2014;50(17): 3029–3038. Epub 2014/10/02.

Parker L, Rychetnik, L, Carter, S. Values in breast cancer screening: an empirical study with Australian experts.  BMJ Open. 2015;5(5):e006333.

Carter SM, Williams J, Parker L, Pickles K, Jacklyn G, Rychetnik L, Barratt A. Screening for cervical, prostate and breast cancer: how should the evidence be interpreted?  American Journal of Preventive Medicine 2015; 49(2),274-85.

Williams JH, Carter SM, Rychetnik L. Information provision in cervical screening in Australia. The Medical Journal of Australia. 2014;201(5):295-7. Epub 2014/08/29.

Rychetnik L, Carter SM, Abelson J, Thornton H, Barratt A, Entwistle VA, et al. Enhancing Citizen Engagement in Cancer Screening Through Deliberative Democracy. Journal of the National Cancer Institute 2013;105(6):380-6.

Rychetnik, L., Carter, SM., Barratt, A., Irwig, L. (2013), Expanding the evidence on cancer screening: the value of scientific, social and ethical perspectives. The Medical Journal of Australia. 198(10), 536-539.